Data Presentation: Topline Data from Part 2 of the MOXIe Trial of Omaveloxolone in Patients with Friedreich’s Ataxia

Part 2 of MOXIe was a Phase 2 international, multicenter, double-blind, randomized, and placebo-controlled study in patients with Friedreich’s ataxia, a rare, progressive, and debilitating genetic disorder with no approved treatments.